Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wesley Prichard

Gastroenterology Lakewood, CO Doctor of Osteopathy

NPI 1194142166 CMS profile 4084316

13952 Denver West Pkwy Ste 100, Lakewood, CO 80401

Open in the dashboard

General payments

$6,623

257 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$222,217 paid to institutions, not to them · program year 2025

Through program year 2025, Wesley Prichard of Lakewood, CO is reported in the CMS Open Payments database as having received $6,623 across 257 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $222,217 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,252 39
2024 General $1,448 72
2023 General $1,194 60
2022 General $889 43
2021 General $534 26
2020 General $579 9
2019 General $728 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wesley Prichard
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Wesley Prichard were reported at $1,252. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Wesley Prichard Gastroenterology median Middle half National median
2019 $728 $417 $126–$1,100 $163
2020 $579 $224 $74–$624 $114
2021 $534 $352 $106–$1,054 $132
2022 $889 $448 $129–$1,270 $149
2023 $1,194 $533 $150–$1,390 $160
2024 $1,448 $605 $160–$1,606 $164
2025 $1,252 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,591 108 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $645 22 payments
  3. Gilead Sciences, Inc. $585 19 payments
  4. Celgene Corporation $445 24 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $388 15 payments
  6. Regeneron Healthcare Solutions, Inc. $349 14 payments
  7. Pfizer Inc. $288 10 payments
  8. Janssen Biotech, Inc. $234 10 payments
  9. Genzyme Corporation $173 2 payments
  10. Allergan Inc. $115 1 payment
  11. Other $811 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,237 254 payments
  2. Grant $335 1 payment
  3. Education $51 2 payments
Products named General payments · program years 2019–2025
  1. LINZESS $619 31 payments
  2. RINVOQ $598 37 payments
  3. HUMIRA $548 16 payments
  4. CREON $507 30 payments
  5. MAVYRET $482 9 payments
  6. ZEPOSIA $445 24 payments
  7. ENTYVIO $403 15 payments
  8. XIFAXAN $388 15 payments
  9. DUPIXENT $349 14 payments
  10. STELARA $300 9 payments
  11. Other $2,225 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

330

Median for Gastroenterology: 569

Drug cost

$212,801

Median for Gastroenterology: $104,976

Branded share of claims

50.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 43 $172,916
Creon Lipase/Protease/Amylase Brand 13 $34,968
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 98 $1,735
Omeprazole Generic 86 $1,423
Pantoprazole Sodium Generic 64 $917
Ondansetron Odt Ondansetron Brand 13 $578
Famotidine Generic 13 $263

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$69,617

Medicare's payments for the services billed

Medicare patients

287

Average age 72

Services billed

600

150 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 38%
Depression 25%
Diabetes 22%
Ischemic heart disease 22%
Chronic kidney disease 22%
Osteoporosis 18%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $157
$157 — —
RINVOQ
  • AbbVie, Inc. $151
$151 — —
LINZESS
  • AbbVie, Inc. $144
$144 — —
ZEPOSIA
  • Celgene Corporation $140
$140 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $105
  • GENZYME CORPORATION $24
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record